

Early-phase clinical trials for central nervous system (CNS) drugs require therapeutic and technical expertise to address scientific, operational, and recruitment challenges unique to this field. With **30+ years of experience**, our CNS Center of Excellence is led by experienced Principal Investigators, clinicians, and neuroscientists, ready to design and execute even the most complex early-phase CNS trials.

Why Choose Altasciences for Your CNS Program?

✓ Accelerated Development—One Partner, Fewer Handoffs

Maintain data continuity and accelerate development timelines by up to 40% with end-to-end capabilities in toxicology, clinical pharmacology, bioanalysis, formulation, and manufacturing.

✓ Deep CNS Expertise and Observatory Capabilities

Access a full spectrum of services, including human abuse potential, driving simulation, cognitive assessments, CSF sampling, EEG/ERP, pain models, dependence evaluation, and studies of psychedelic compounds.

✓ Advanced Preclinical and Regulatory Support

Enable a smooth, regulatory-ready transition to first-in-human trials with IND-enabling toxicology and safety pharmacology expertise across species—with emphasis on complex CNS and psychedelic programs.

✓ Clinical Units Built for CNS Trials


Leverage adaptable, DEA-licensed clinical pharmacology units for psychedelic and CNS trials, supported by secure pharmacy systems, flexible inpatient configurations, and experienced staff.

✓ Formulation and Manufacturing for Challenging Molecules

Benefit from our specialized approaches, such as nanomilling, solubility enhancement, and innovative dosage forms, to effectively address CNS drug delivery challenges. DEA-licensed cGMP manufacturing facilities support your highly potent and controlled substances.

200+

CNS studies completed



Targeted Recruitment for CNS Studies

We can identify and enroll specialized or patient cohorts for your early-phase CNS studies, including participants diagnosed with a variety of conditions, from our centralized database of **400,000+ participants**.

- ADHD
- Age-related cognition issues
- Anxiety and panic disorders
- Binge eating disorder
- Epilepsy
- Fibromyalgia
- Major depressive disorder
- Migraine
- Neuropathies
- Osteoarthritis
- Pain
- Premenstrual dysphoric disorder
- Restless leg syndrome
- Sleep disorders
- Substance use disorders
- Patients with other CNS disorders (upon request)

With participant-centric processes, clear communication, structured preparation, and continuous medical oversight, we establish the conditions to promote retention, compliance, and consistency throughout your study.

Cognitive Testing

Expert neuroscientists design and implement targeted neurocognitive assessments to evaluate drug effects on brain function. In **partnership with Cambridge Cognition**, a global leader in digital neuroscience technology, we deliver validated, non-invasive test batteries that assess key cognitive domains, including:

- complex attention
- learning and memory
- language
- executive function
- social cognition
- perceptual-motor function
- psychomotor performance

Regulatory Readiness

Our start-up approach ensures your protocol is submission-ready, reducing amendment risk and accelerating regulatory approval.

- Development of protocol-specific SOPs
- Rigorous staff and participant training to ensure data consistency and protocol adherence
- Practice sessions before dosing to confirm participant understanding and compliance
- Extensive experience with central IRBs, adaptive trial designs, and global submission standards
- 8-Factor Analysis
- Briefing books and regulatory meeting preparation

Accelerate Your CNS Program With Confidence

Whether you're developing a novel CNS compound or repurposing an existing molecule, we deliver the precision, consistency, and speed that keeps your program moving forward with clarity.